Atlas' Guide to Peptides Foundations

That size is the whole story. Short chains are small enough to fit specific receptor pockets and be cleared quickly, but too fragile to survive the gut. Your body already manufactures thousands of them: insulin, glucagon, oxytocin, growth hormone releasing hormone. Nothing in this field is exotic biology — it is the same messaging layer your endocrine system runs on every day.

What separates a therapeutic peptide from a supplement is specificity. A well-designed peptide binds one receptor family and nudges one pathway. That makes effects narrower and more predictable than a broad-spectrum drug, and it also means a compound with an impressive mechanism can still produce nothing measurable if the pathway it touches was never your limiting factor.

1. 01Receptor agonismThe peptide imitates a signal your body already uses and switches a receptor on — the mechanism behind most metabolic and growth-hormone compounds.
2. 02Receptor blockadeThe peptide occupies a receptor without activating it, muting a signal that is running too hot.
3. 03Secretagogue actionRather than replacing a hormone, the peptide asks the gland to release more of your own — which keeps natural pulsatility and feedback loops partly intact.
4. 04Local tissue signallingThe peptide acts near the injection or application site on angiogenesis, collagen synthesis or inflammatory tone, rather than systemically.
5. 05Enzyme and transport modulationThe peptide changes how fast something is broken down, taken up or transported, shifting availability without adding new signal.

Three properties then decide how a mechanism translates into practice. Half-life sets dosing frequency — minutes means multiple daily injections, days means weekly. Receptor density in the target tissue sets how much of the effect lands where you want it. And feedback determines whether the body adapts around you, which is why some protocols degrade after six weeks and others hold.

1. 01Preclinical EvidenceAnimal, in-vitro or purely mechanistic work. Interesting, directional, and historically a poor predictor of human outcomes. Treat as a hypothesis.
2. 02Limited Human EvidenceReal human data exist, but the studies are small, early-phase, mixed, indirect or route-specific. Enough to justify curiosity, not enough to promise a result.
3. 03Strong Human EvidenceSubstantial randomised or late-phase human trials with clinically meaningful outcomes, or established clinical use for the stated claim.

Four questions to ask of any study someone quotes at you:

• Species and route. A result from intravenous dosing in rodents rarely survives translation to subcutaneous dosing in humans.
• Population. Effects in a deficient or diseased cohort routinely shrink to nothing in healthy trained adults.
• Endpoint. A biomarker moving is not the same as a person moving better. Ask whether anything was measured that you care about.
• Effect size and n. A statistically significant change in twelve subjects can still be practically irrelevant.

1. 01Bring the vial to room temperatureCold glass and cold diluent make mixing harder and can shock some peptides. Let it sit out for a few minutes.
2. 02Swab both stoppersAlcohol wipe on the peptide vial and the diluent vial, every single time, and let them dry.
3. 03Draw your diluentBacteriostatic water for multi-use vials; sterile water only if the vial will be finished quickly, since it has no preservative.
4. 04Run it down the glass wallAim the needle at the inside wall so the stream does not jet directly onto the powder cake. Peptides are shear-sensitive.
5. 05Swirl, never shakeRotate gently until clear. Shaking denatures the chain and foams the solution. Cloudiness or floating particles after full dissolution means do not use it.
6. 06Label and refrigerateWrite compound, concentration and reconstitution date on the vial. Untracked vials become guesswork within a week.

Choose your diluent volume for readable numbers, not for tradition. If your target dose lands on 3 units, a small misread is a 33% error; reconstitute thinner so the same dose lands on 20 units and the same misread is 5%.

1. 01Wash hands, then swab the siteAbdomen at least two finger-widths from the navel, outer thigh, or the back of the upper arm. Let the alcohol dry fully — injecting through wet alcohol stings.
2. 02Draw the dose and clear airTap the barrel, push the plunger to the marked unit line, and confirm the number before the needle touches skin.
3. 03Pinch and insertLift a fold of fat, insert at 45–90° depending on how much tissue you have, and push slowly and steadily.
4. 04Withdraw and pressStraight out, then light pressure with clean gauze. Do not massage the site.
5. 05Rotate sitesMap a rotation across quadrants. Repeatedly hitting the same spot causes lumps, scar tissue and erratic absorption.
6. 06Dispose properlyOne needle, one use, into a proper sharps container. Never recap and reuse.

Discard on sight for any of the following: visible particulates after full dissolution, persistent cloudiness, discolouration, a cracked stopper, or a vial you cannot date. The cost of a replacement vial is always lower than the cost of injecting a contaminated one.

Ask one question of any compound: does continuous exposure blunt the response, or suppress an upstream gland? Compounds acting on the pituitary axis generally answer yes, which is why they are run in defined blocks with off periods. Local repair signalling is typically run for the length of the injury timeline and then stopped because the job is done, not because the receptor tired.

1. 01Define the outcome before you startWrite down the measurement that will tell you it worked — a lift, a weight, a sleep score, a lab value. No metric, no cycle.
2. 02Change one variable at a timeStarting three compounds in the same week means you learn nothing about any of them.
3. 03Titrate up, do not open highBegin at the low end of a documented range and step up only if the outcome metric is flat and side effects are absent.
4. 04Set an end date on day oneOpen-ended use is how a trial becomes a habit without anyone deciding it should.
5. 05Take a real washoutAn off period long enough for receptors to reset and for you to see what the baseline actually is now.

There are three defensible reasons to combine:

• Complementary pathways. One compound handles a systemic signal while another handles local tissue work.
• Kinetic pairing. A short-acting and a long-acting compound covering different parts of a 24-hour window.
• Side-effect offset. One compound counters a known, documented downside of the other.

A practical cadence: baseline, a checkpoint six to eight weeks in, and a post-cycle draw after the washout. Track subjective markers on the same schedule — sleep quality, training performance, appetite, mood — because those often move before the labs do.

1. 01Pharmacological riskThe compound's own known effects — nausea, water retention, altered glucose handling, blood-pressure changes, flushing. Documented per compound on its Atlas page.
2. 02Procedural riskContamination, injection-site infection, abscess and needle injury. Entirely preventable with proper technique.
3. 03Product riskWrong compound, wrong quantity, endotoxin contamination, residual solvents. This is the dominant risk in an unregulated supply chain.
4. 04Decision riskDose errors, stacking blind, ignoring symptoms, running open-ended, and skipping blood work. Statistically the biggest category.

Higher-caution groups: anyone with a personal or family history of cancer, active or treated thyroid disease, diabetes, cardiovascular disease, kidney or liver impairment, pregnancy or breastfeeding, and anyone under 25 whose growth plates and endocrine axes are still settling. Tested athletes should also assume most of these compounds are banned in competition and check the current prohibited list themselves.

1. 01Third-party testing, not in-house claimsA certificate produced by the seller is marketing. Look for an independent laboratory named on the report.
2. 02Match the batchThe certificate must reference the batch number printed on your vial. A generic PDF for the product line proves nothing about your vial.
3. 03Read the actual assaysHPLC for purity, mass spectrometry for identity, and — the one most people skip — an endotoxin or sterility result.
4. 04Check quantity, not just purity99% pure is meaningless if the vial contains 3 mg where the label says 5 mg. Quantitative content should be stated.
5. 05Inspect physicallyA proper lyophilised cake, an intact stopper, a legible label, an unbroken seal.
6. 06Be suspicious of priceSynthesis and testing cost money. Prices far below the market are usually paid for by skipping one of them.

• Approved medicines. Licensed for specific indications, prescription-only, manufactured to pharmaceutical standards.
• Compounded or off-label. Legal to prescribe in some jurisdictions under clinician supervision, with quality that depends heavily on the pharmacy.
• Research chemicals. Sold for laboratory use, not approved for human administration, and outside any consumer safety regime.
• Controlled or prohibited. Restricted outright in some countries, and separately banned in tested sport regardless of local legality.

Import rules, personal-possession thresholds and prescription requirements differ enormously between countries and can change without notice. Verify your own jurisdiction's current position — an Atlas page is not a legal clearance.

Agonist

A molecule that binds a receptor and activates it, mimicking the body's own signal.

Antagonist

A molecule that binds a receptor and blocks it, preventing the native signal.

Bioavailability

The fraction of an administered dose that actually reaches circulation intact.

Half-life

The time it takes for half of a dose to be cleared. Drives how often you dose.

Secretagogue

A compound that prompts a gland to release a hormone it already produces.

Subcutaneous (SubQ)

Injection into the fat layer under the skin. The default route for most peptides.

Intramuscular (IM)

Injection into muscle tissue. Faster absorption, more discomfort.

Bacteriostatic water

Sterile water with 0.9% benzyl alcohol, used to reconstitute and preserve multi-use vials.

Lyophilised

Freeze-dried into a stable powder. The state most peptides ship in.

Titration

Starting low and stepping a dose upward while watching for response and side effects.

Tachyphylaxis

Diminishing response to the same dose over time as receptors desensitise.

IGF-1

Insulin-like growth factor 1. The main downstream marker used to gauge GH-axis activity.